The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BridgeBio Pharma, Inc. announced that it will present research findings related to its drug acoramidis for treating variant transthyretin amyloid cardiomyopathy (ATTR-CM) at the upcoming Annual ...

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE)-- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio” or the "Company”), a biopharmaceutical company focused on developing medicines for genetic ...

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p0.001), which is associated with reduced ACM, further reinforcing its differentiated ...

BridgeBio Pharma Inc (NASDAQ:BBIO) announced the presentation of detailed results from its Phase 3 ATTRibute-CM study of acoramidis for ATTR-CM at the European Society of Cardiology Congress 2023.

- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - ...

PALO ALTO, Calif., Sept. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, ...

PALO ALTO, Calif., Aug. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, ...

- Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p<0.0001) - The difference in cumulative events increased ...